, Senger 6 and Keck 7 of the principal player in angiogenesis, vascular endothelial growth factor A (VEGF-A, also referred to as VEGF). VEGF-A exists in multiple isoforms of variable exon content and strikingly contrasting properties and expression patterns. This range of products from the 8-exon VEGF-A gene on chromosome 6 renders VEGF-A biology complex (FIG. 1) , and alterations in isoform expression in cancer may be instructive for other genes involved in malignant change in general 8 and in the pro-angiogenic cascade in particular. Indeed, the products of VEGF-A, rather than just being targets for inhibition, may hold the key to impeding tumour growth and act as a model for controlling the qualitative expression of other malignancy-associated genes.
In tumours, and most other angiogenic situations, new vessel development is primarily dependent on this 46 kDa glycoprotein acting on its endothelial cell receptors VEGF receptor 1 (VEGFR1), VEGFR2 and the co-receptor neuropilin 1. This view is supported by the finding that even heterozygous Vegfa knockouts are embryonically lethal 9 .
The first VEGF-A isoform described, VEGF-A 165 (ReF. 5) , has been extensively investigated for its function, signalling, expression and roles in cancer 10 . Other isoforms including VEGF-A 121 , VEGF-A 145 , VEGF-A 148 , VEGF-A 183 , VEGF-A 189 and VEGF-A 206 , identified between 1989 and 2003, are generated by alternative splicing of exons 6 and 7, which code for motifs that bind to the highly negatively charged glycosaminoglycan carbohydrate heparin and similar molecules. In 2002, an additional isoform was identified 11 : VEGF-A 165 b, which is generated by exon 8 distal splice site (DSS) selection. This DSS choice can also occur in conjunction with exon 6 and 7 inclusion or exclusion. It therefore became apparent that VEGF-A mRNA splicing generates two families of proteins that differ by their C′ terminal six amino acids (FIG. 1) , and these are termed VEGF-A xxx (pro-angiogenic) and VEGF-A xxx b (anti-angiogenic) 12 , xxx denoting the amino acid number of the mature protein.
Details of the molecular control of C′ terminal splice site choice (and the proangiogenic-anti-angiogenic balance) are emerging 13 (FIG. 2) . Upstream factors governing VEGF-A expression include hypoxia, cytokines, sex hormones, chemokines and growth factors (reviewed in ReFs 10, 14) , although most studies have assessed VEGF-A expression using agents that would not distinguish between the two VEGF-A families. Subsequent downstream VEGF-A signalling of the conventional proangiogenic VEGF-A xxx isoforms has been identified (reviewed in ReFs 15, 16) (FIG. 3a) .
Alterations in these pathways have not been identified in as much detail for the VEGF-A xxx b family (FIG. 3b) .
In this article we consider the significant functional differences between the isoform families and the progress made in determining the mechanistic differences between them.
Expression of VEGF-A xxx b isoforms Increased expression of VEGF-A appears to be a characteristic in several pathologies, including cancer, arthritis and cardiovascular disease, but it is upregulated from a basal level in normal tissues. The development of antibodies and probes that specifically detect VEGF-A xxx b isoforms by enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, western blotting and quantitative PCR has revealed that basal expression is dominated by VEGF-A xxx b isoforms in many tissues 17 . In human vitreous fluid, circulating plasma, urine, renal cortex, colonic epithelium, bladder smooth muscle, lung and pancreatic islets, VEGF-A xxx b isoforms constitute more than or close to half of the total VEGF-A expressed 12, 17, 18 . To date, the placenta, in which angiogenesis is known to occur, is the only normal tissue identified to have VEGF-A xxx b constituting significantly less than half its total VEGF-A 17 .
In primary cultured cells, such as differentiated visceral glomerular epithelial cells (podocytes), retinal pigmented epithelial cells and colonic epithelial cells, VEGF-A xxx b isoforms predominate 13, 19, 20 . However, in melanoma, colorectal carcinoma and bladder cancer cells as well as proliferating dedifferentiated podocytes, VEGF-A xxx isoforms comprise the majority of VEGF-A [19] [20] [21] . VEGF-A xxx b structure and properties Receptor binding, downstream signalling and pharmacology. VEGF-A 165 b differs from VEGF-A 165 only in the carboxy-terminal six amino acids, a change from CDKPRR to SLTRKD 11 . The unique C′-terminal six amino acids encoded by exon 8b endow VEGF-A 165 b (and other VEGF-A xxx b isoforms) with radically different properties to those of VEGF-A 165 . The key residue alterations are the loss of the cysteine and the replacement of the highly positively charged arginines present in VEGF-A 165 with neutral lysine-aspartic acid in VEGF-A 165 b 22 . These differences have profound implications for structure (FIG. 4) Abstract | The physiology of microvessels limits the growth and development of tumours. Tumours gain nutrients and excrete waste through growth-associated microvessels. New anticancer therapies target this microvasculature by inhibiting vascular endothelial growth factor A (VEGF-A) splice isoforms that promote microvessel growth. However, certain VEGF-A splice isoforms in normal tissues inhibit growth of microvessels. Thus, it is the VEGF-A isoform balance, which is controlled by mRNA splicing, that orchestrates angiogenesis. Here, we highlight the functional differences between the pro-angiogenic and the anti-angiogenic VEGF-A isoform families and the potential to harness the synthetic capacity of cancer cells to produce factors that inhibit, rather than aid, cancer growth. (FIG. 5) . VEGF-A 165 also stimulates robust phosphorylation of tyrosine 1175, resulting in activation of phospholipase Cγ, phosphoinositide 3-kinase and diacyl glycerol production, and activation of the Raf-MEK-Erk pathway in a protein kinase C-dependent 27 , Ras-independent manner 28 (FIG. 3) . These events are crucial for the activation of pro-angiogenic gene expression in endothelial cells, particularly as they lead to the production of the matrix metalloproteinases that are required for invasion through the basement membrane and the initiation of endothelial cell migration and angiogenesis 29 . Notably, VEGF-A 165 b does not bind neuropilin 1, as the basic carboxy-terminal amino acids essential for neuro pilin 1 binding are absent 22 . The functional difference between VEGF-A 165 and VEGF-A 165 b might be determined by absence of neuropilin 1 co-signalling, or it might be due to unique downstream signalling , the DSS-selected mRNA encoding a protein of exactly the same length. Exon 6a′ occurs in VEGF-A 183 as a result of a conserved alternative splicing donor site in exon 6a and is 18 bp shorter than full-length exon 6a. VEGF-A 148 is a truncated isoform splicing from exon 7a into exon 8a out of frame and resulting in a premature stop codon 71 .
VEGF-A 206 b
has not yet been identified. c | Protein structure of VEGF-A containing the dimerization sites and binding sites for heparin, VEGF-A receptor 1 (VEGFR1; encoded by exon 3) and VEGFR2 (encoded by exon 4), which are present in all isoforms. The six amino acids at the extreme carboxyl terminus of the protein can be either pro-angiogenic (CDKPRR, encoded by exon 8a) or anti-angiogenic (SLTRKD, encoded by exon 8b). The epitopes recognized by most commercial antibodies are in the region of the VEGF-A receptor-binding domains, present in VEGF-A isoforms of both families. UTR, untranslated region. 
Effect of VEGF-A xxx b on non-endothelial cells.
VEGF-A has long been regarded as a family of pro-angiogenic, pro-permeability vasodilator peptides. Two key discoveries have emerged in recent years that have resulted in a radical re-evaluation of VEGF-A biology. One was the identification of the anti-angiogenic VEGF-A xxx b family. Although, 6 years after its description, the number of papers on this anti-angiogenic family equate to 40% of those published in the 6 years after the first discovery of VEGF, this group of isoforms has yet to attract the attention of the majority of VEGF investigators. The reasons for this are unclear but may simply be because it has been overlooked in the vast VEGF-A literature (approximately 200 publications per month) or because the identification of this group has unpalatable implications for all of us. Academically it suggests additional layers of complexity and, in terms of resource allocation, the existence of VEGF-A xxx b suggests that many of the thousands of published manuscripts on VEGF-A may, at best, need re-interpretation or, at worst, require repeating with reagents that differentiate between isoform families. As tools for investigating VEGF-A xxx b isoforms (for example, antibodies, probes and ELISA kits) have now become available, our understanding of the role of VEGF-A xxx b should become clearer.
The second revolution in VEGF-A biology has been that, despite its nomenclature, VEGF-A is not specific to endothelial cells and can also be vital in the function and maintenance of non-endothelial cells. Mutations in the hypoxia response element of the Vegfa promoter can, for example, result in a form of motor neuron disease in mice 30 , which is not associated with angiogenesis. VEGF-A 165 was subsequently shown to be neuroprotective 30 . Inhibition of VEGF-A also results in retinal neurotoxicity both in vitro and in vivo 31 and proteinuria in humans 32 and in rodents 33 . This latter effect could be due to podocyte cytotoxicity, for which both VEGF-A 165 (ReF. 34) and VEGF-A 165 b 18 are in vitro survival factors, perhaps through VEGF-A-dependent phosphorylation of nephrin 35 . VEGF-A 165 b also acts as a paracrine or autocrine survival factor. Treatment of podocytes, retinal pigmented epithelial cells or colonic adenoma cells in vitro with a neutralizing antibody to VEGF-A 165 b that does not bind VEGF-A 165 , even when present in 50-fold excess 18, 20, 36 , results in increased cytotoxicity 13, 18, 20 . Conversely, treatment of these cell types with VEGF-A 165 b reduces cytotoxicity when induced by multiple agents 13, 18, 20 . The receptor-mediated mechanism of action of VEGF-A 165 b-dependent cytoprotection in epithelial cells has not been well defined and indeed may be cell-type-dependent and VEGFR-phenotype-dependent, but these results support the concept that VEGF-A 165 b may elicit distinct signalling pathways. , VEGF-A 165 b-encoding adenoviral constructs 36 and recombinant human VEGF-A 165 b 38, 39 . VEGF-A 165 stimulates endothelial cell migration and proliferation in vitro, vasodilatation 40 , increased endothelial mono layer permeability in vitro 18 , chronically increased vascular permeability in vivo 41 , in vivo angiogenesis 42 and pathological retinal neovascularization in vivo 43 . By stark contrast, VEGF-A 165 b does not stimulate these responses, and inhibits several VEGF-A 165 -mediated processes: endothelial cell . These SFs recognize cis-acting RNA splicing sequences in the pre-mRNA and both splicing sites (SS) -5′ donor (5′SS) or 3′ acceptor sites -can be recognized. Both 3′ proximal SS (3′PSS) and distal SS (3′DSS) are indicated. The particular splicing factors recruited are dependent on the sequence. These SFs can be regulated by SF kinases (SFKs), which are regulated by cell signalling molecules (CSMs) downstream of growth factors (GFs). b | Regulation of VEGF-A C′ terminal PSS selection by insulin-like growth factor (IGF). IGF activates protein kinase C (PKC), which results in phosphorylation of SR protein kinases (SRPKs). These can activate the ASF-SF2 splicing factor, which favours PSS selection. This process may be dependent on the presence of hypoxia-inducible factor (HIF), a transcription factor involved in VEGF-A xxx upregulation 13 . Other SFs and kinases may also be involved in PSS and DSS selection, denoted by '??'. c | Factors affecting VEGF-A C′ terminal DSS selection. Transforming growth factor β1 (TGFβ1) results in p38 mitogen-activated protein kinase activation and subsequent activation of the kinases CLK1 and CLK4. CLK1 and CLK4 phosphorylate the splicing factor SRP55, resulting in DSS selection and production of VEGF-A xxx b 13 . It is also possible that ASF-SF2 is inactivated by CLK1 and CLK4, or that phosphorylation of the SFs could change their location, degradation or binding affinity. This scheme summarizes the limited data available. ? Nature Reviews | Cancer . VEGF-A 165 b does not increase chronic microvascular permeability in vivo 44 and reduces conditionally immortalized human glomerular endothelial cell mono layer permeability in vitro 18 . VEGF-A 165 b also inhibits in vivo angiogenesis in the rat mesentery when VEGF-A 165 overexpression is driven by an adenoviral vector 36 . In addition, VEGF-A 165 b inhibits pathological angiogenesis in murine tumour models 20, 37, 39 , physiological angiogenesis in mam mary tissue in transgenic mice 45 , VEGF-A 165 -mediated angiogenesis in the chick chorioallantoic membrane assay 26 and VEGF-A 165 -mediated angiogenesis in the rabbit corneal eye pocket model 36 . Finally, recombinant human VEGF-A 165 b inhibits hypoxia-mediated retinal angiogenesis in vivo in murine models of retinopathy of prematurity 38 and human tumour growth in mice 39 . Both VEGF-A 165 and VEGF-A 165 b bind VEGFR2 with equal affinity 20, 36 but VEGF-A 165 b fails to stimulate angiogenesis in vivo 26, 36, 45 . These initial observations lent credence to the view that VEGF-A 165 b was likely to demonstrate classical competitive 'key-in-the-lock' inhibition, even if the molecule was completely inert. However, further work by Ballmer-Hofer's group 26 has shown that a truncated isoform of VEGF-A 165 , VEGF-A 159 , which lacks the amino acids encoded by exons 8a and 8b, does not inhibit VEGF-A 165 -mediated angiogenesis, despite binding to VEGFR2 and lacking angiogenic activity itself, which suggests that the presence of exon 8b in VEGF-A 165 b may have a specific inhibitory contribution. Therefore, it is as yet unclear whether the profound difference in cellular behaviour induced by VEGF-A 165 b relative to VEGF-A 165 is due to a qualitative alteration in signalling (that is, differing signalling molecules are used) or a quantitative alteration in signalling (that is, the downstream signalling is insufficient), or whether both mechanisms are functional. There is data supporting the quantitative hypothesis 25 but the qualitative hypothesis has only circumstantial evidence to date.
Effect of VEGF-
In tumours, overexpression of transfected VEGF-A 165 b delays the growth of melanoma 36 , kidney 37 , colon 20 , prostate 37 and Ewing sarcoma 37 tumours. Furthermore, recombinant human VEGF-A 165 b inhibits developing and established solid tumour growth in nude mice when given subcutaneously or by intra-peritoneal injection 39 . Tumours treated with VEGF-A 165 b are paler, less haemorrhagic and visibly less vascularized, with reduced microvascular density and increased necrosis 39 . Dose-response studies show complete inhibition of established tumour growth by 100 µg biweekly injection of recombinant VEGF-A 165 b 39 . Furthermore, parenteral treatment with recombinant human VEGF-A 165 b can reduce the growth of disseminated metastatic melanoma tumours 46 . All these data are consistent with a cancer-associated switch from anti-to proangiogenic VEGF-A isoform expression by alteration of splicing. This switch to pro-angiogenic VEGF-A isoforms has also been shown at the mRNA level in prostate 37 , renal 11 and bladder cancer 21 , and at the protein level in bladder cancer 21 and metastatic but not non-metastatic melanoma 47 . The study in melanoma demonstrated that primary melanomas from patients that later developed distant metastases expressed less VEGF-A 165 b than those from patients that were disease-free 8 years later 47 . Furthermore, a low level of VEGF-A 165 b expression is a potential bio marker for poor prognosis in colonic carcinoma 48 . report suggests that pegaptinib, the VEGF-A aptamer (an oligonucleotide ligand that displays high-affinity binding to a molecular target), does not bind VEGF-A 165 b 49 , although similar data are not yet available for most other anti-VEGF-A agents, including VEGF-TRAP (aflibercept -a unique fusion protein that has a high affinity for all isoforms of VEGF-A as well as for placental growth factor), and VEGFR tyrosine kinase inhibitors (TKIs), such as sunitinib and sorafenib. However, it is possible that the combined effect of recombinant VEGF-A 165 b and TKIs that target VEGFR2 may have increased efficacy over treatment with a VEGFR TKI alone, as VEGF-A 165 b is not simply a non-specific inhibitor of VEGFR2 but can actively antagonize VEGFR2 angiogenic signalling 25 and possibly also VEGFR1 (ReF. 44) .
Heterogeneity of VEGF-

Therapeutic implications
VEGF-A 165 b expression has a profound effect on the efficacy of bevacizumab. In mice injected with VEGF-A 165 b-expressing colonic cancer cells, the tumours grow more slowly than in those bearing VEGF-A 165 -expressing cancer cells. However, the dose of bevacizumab required to prevent tumour growth in VEGF-A 165 -expressing tumours had absolutely no effect on VEGF-A 165 b-expressing tumours 20 . This startling finding suggests that treatment of patients with tumours expressing significant levels of VEGF-A xxx b with bevaciumab may not be effective, because VEGF-A 165 b will inhibit the effect of this anti-VEGF-A antibody. Conversely, this model would predict that bevacizumab treatment would be most effective in patients whose tumours produce an excess of VEGF-A xxx isoforms.
Recombinant human VEGF-A 165 b.
It has yet to be established whether the inhibition of bevacizumab by VEGF-A 165 b expression can be predicted by assessing the VEGF-A 165 :VEGF-A 165 b ratio in patients. If this is indeed the case, current assays for VEGF-A xxx b will need to be developed for clinical use or standardized immunohistochemical procedures will be required. However, an alternative approach is that VEGF-A 165 b (the most widely studied VEGF-A xxx b isoform) or other VEGF-A xxx b isoforms may be therapeutic themselves. In principle, VEGF-A 165 b would have potential advantages over a number of existing anti-angiogenic therapies. These include its endogenous nature and the lack of side effects such as hypertension and proteinuria that are associated with the inhibition of VEGF-A xxx
39
. Anti-VEGF-A therapy has been shown to cause normal capillary loss 50 , and endothelial cell-specific knockout of all VEGF-A isoforms (including VEGF-A 165 b) results in adult mortality in mice due to endothelial cell apoptosis and subsequent haemorrhage 51 . There are therefore sound reasons to suspect that VEGF-A 165 b-based therapy will be less problematic than agents that target all VEGF-A isoforms. Thus, the identification of VEGF-A xxx -specific antagonists (for example, anti-exon 8a C′-terminal antibodies) may benefit from precise targeting. The next generation of anti-VEGF-A therapies might derive from such a design.
Tumour splicing hypothesis. The control of divergent physiological properties from one gene resides with mRNA splicing, stability and translation. The transcripts of the majority (70%) of human genes splice 52 , in that they code for multiple isoforms, many of which have strikingly different properties. Splicing is co-transcriptional, and the consensus sequences at the 5′ and 3′ sites are recognized by the splicing apparatus early in the splicing process -that is, the splicing choice occurs early in the birth of an RNA molecule. Splicing mechanisms in mammals are being elucidated using models such as fibronectin 53 and β-globin 54 and there is now considerable evidence that regulation of splicing is a key event in cancer progression 8, 55 . The process is mediated by splicing proteins, which form the spliceosome 56 , and is regulated by splicing regulatory factors. Progress made in defining the mechanisms of VEGF-A exon 8 splice site choice 13 indicates two cysteine (C)-bonded double anti-parallel β sheet structures (brown arrows) separated by an α helix (blue cylinder). This structure is highly mobile and rotates around the hinge, and could pass through the VEGF receptor 2 (VEGFR2) binding region but not the VEGFR1 region (yellow circles) 75, 76 . c | Proposed structure of amino acids 108-165 of VEGF-A 165 . The C′ terminal six residues include a cysteine with two positively charged arginines (RR) that are proposed to interact with the VEGFR binding domain 22 to activate intracellular torsional rotation of VEGFR2. The RR motif therefore acts as a molecular switch by inducing a conformational change in VEGFR2. A disulphide bond 77 (shown in orange) between cysteines 146 and 160 is required for VEGF-A 165 activity 78 and ensures that the C terminus is maintained at close proximity to the neuropilin 1 binding domain (NPBD). 65 and collagen IV (tumstatin) 66 have also been characterized. Common splicing mechanisms allowing anti-angiogenesis to be switched to angiogenesis 67 in disease or remodelling have been proposed 67 , and these may extend to many non-angiogenesisrelated proteins that also exist as multiple isoforms and drive tumour progression.
Indeed there are many non-angiogenic cancer-related genes that have splice isoforms with antagonistic properties and it is becoming increasingly apparent that similar factors can orchestrate the splicing of angiogenic and non-angiogenic malignancy-associated genes 8 . For example, exclusion of exon 3 of the FGFR1 in gliomas produces the tumourpromoting isoform FGFR1β. This exon exclusion results from the loss of the splicing factor SRP55 (ReF. 68) , which also reduces VEGF-A C′-terminal DSS selection, shifting the VEGF-A xxx versus VEGF-A xxx b balance towards angiogenesis 13 . Therefore, the dual phenomena of a molecular switch to stimulate unregulated malignant cell proliferation and the angiogenic switch as described by the late J. Folkman 69 may have different cellular mechanisms, but alternate splicing may well provide a mechanism explaining the connection between malignancy and angiogenesis, as Folkman hypothesized.
In summary, VEGF-A xxx b isoforms are key regulators of angiogenesis in health and disease. Exogenously (intravenously) administered recombinant VEGF-A 165 b appears to accumulate in tumours (presumably because it targets VEGFR2-bearing tumour microvessels) and therefore has increased tumour bio-availability 39 . Thus, administration of recombinant VEGF-A xxx b isoforms The charged residues at the carboxy-terminal end of the VEGF-A 165 molecule (omitted for clarity) are required for VEGFR activation and, in receptor tyrosine kinases, this is thought to occur through torsional rotation of the intracellular domain bringing together the split kinase domains. Tyrosine 1054 is located at the mouth of the ATP binding pocket of the tyrosine kinase and, once phosphorylated, prevents the binding pocket from closing, thus resulting in a stable open structure. This results in formation of a persistently functional kinase from the split kinase domains, resulting in sustained cis-and trans-phosphorylation of the tyrosine residues on the intracellular tail, even in the presence of phosphatases. Robust tyrosine phosphorylation also results in the activation of angiogenic signalling pathways (FIG. 3) . b | VEGF-A 165 b binds the VEGFR2 binding site with equal affinity to VEGF-A 165 but does not bind neuropilin 1 (NRP1). The C′ terminus of VEGF-A 165 b is neutral and there is insufficient torsional rotation for tyrosine 1054 to be phosphorylated, although weak phosphorylation of the other tyrosines can occur. Thus, the ATP binding pocket closes and the phosphorylated tyrosines can be rapidly dephosphorylated by phosphatases and trafficked much more quickly. As a result, angiogenic signalling pathways are not activated 25 .
could be a novel therapeutic approach in the short term. However, the most effective but also the most challenging approach in the long term may be to allow cancer VEGF-A transcription to proceed unhindered but to control splicing such that the spliceosome opts for exon 8 DSS selection in place of exon 8 PSS selection. This would effectively cause the cancer to switch off its own nutrient supply. Indeed, given that the VEGF-A promoter contains a hypoxia response element 70 , the more hypoxic the tumour became, the more effective this switch might be.
